Who is sponsoring NCT05710380?

NCT05710380 is sponsored by University of Chicago.

What drugs are being tested in NCT05710380?

Interventions in NCT05710380: Risk Map Decision Support System (DSS)., Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging (MRI) Guided Biopsy.

What condition does NCT05710380 study?

NCT05710380 studies Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm.

Is NCT05710380 still recruiting?

NCT05710380 is currently recruiting now. Last updated 1 October 2025.

Last reviewed 2025-10-01 · How we verify

NCT05710380

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Recruiting now NA Last updated 1 October 2025

What this trial tests

NA trial testing Risk Map Decision Support System (DSS). in Prostate Cancer in 180 participants. Currently enrolling.

Timeline

26 April 2023

Primary endpoint
1 May 2026

1 May 2026

Quick facts

Lead sponsor	University of Chicago
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	180
Start date	26 April 2023
Primary completion	1 May 2026
Estimated completion	1 May 2026
Sites	1 location across United States

Drugs / interventions tested

Risk Map Decision Support System (DSS).
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) Guided Biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
Prostate Neoplasm — all drugs for Prostate Neoplasm →

Sponsor

University of Chicago

Who can join

18 and older, male only, with Prostate Cancer or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.
Chatterjee A, Yousuf AN, Engelmann R, Harmath C, et al · · 2025 · cited 3× · PMID 39836080 · DOI 10.1148/rycan.240156
MRI-based virtual pathology of the prostate.
Chatterjee A, Dwivedi DK. · · 2024 · cited 2× · PMID 38856839 · DOI 10.1007/s10334-024-01163-w

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05710380 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 1 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05710380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing